Correlation between serum IL-1β and miR-144-3p as well as their prognostic values in LUAD and LUSC patients

被引:35
作者
Wu, Chen [1 ,2 ,3 ]
Xu, Bin [3 ,4 ]
Zhou, You [3 ,4 ]
Ji, Mei [1 ,3 ]
Zhang, Dachuan [5 ]
Jiang, Jingting [2 ,3 ,4 ]
Wu, Changping [1 ,2 ,3 ]
机构
[1] Soochow Univ, Affiliated Hosp 3, Dept Oncol, Changzhou 213003, Peoples R China
[2] Soochow Univ, Inst Cell Therapy, Changzhou 213003, Peoples R China
[3] Jiangsu Engn Res Ctr Tumor Immunotherapy, Changzhou 213003, Peoples R China
[4] Soochow Univ, Affiliated Hosp 3, Dept Biol Treatment, Changzhou 213003, Peoples R China
[5] Soochow Univ, Affiliated Hosp 3, Dept Pathol, Changzhou 213003, Peoples R China
基金
中国国家自然科学基金;
关键词
LUAD; LUSC; IL-1; beta; miR-144-3p; prognosis; EPITHELIAL-MESENCHYMAL TRANSITION; LUNG-CANCER CELLS; BREAST-CANCER; INFLAMMATION; EXPRESSION; CELECOXIB; MICRORNA; BLOOD; RNA;
D O I
10.18632/oncotarget.13042
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: IL-1 beta is an essential factor of inflammation initiation, and it also promotes malignant transformation, indicating its tumorigenic property. We aimed to investigate the correlation between IL-1 beta and miR-144-3p as well as their prognostic values in LUAD and LUSC patients. Results: The IL-1 beta level in both LUAD and LUSC patients was significantly higher than that of healthy donors (P < 0.001). In both populations, patients with low IL-1 beta level had better prognosis than high IL-1 beta level (P < 0.001 and P = 0.010, respectively). In A549 cells, miR-144 showed the biggest expression change (-4.38 fold) after IL-1 beta exposure. In LUAD patients, a negative correlation was detected between IL-1 beta and miR-144-3p (r = -0.540, P < 0.001) and the high miR-144-3p group had better prognosis (P = 0.003), which was validated by TCGA data. Clinical stage, IL-1 beta and miR-144-3p were independent risk factors in LUAD patients. In vitro, IL-1 beta and miR-144-3p antagomir could enhance proliferation and miR-144-3p mimics would attenuate the promoting effect of IL-1 beta. Materials and Methods: ELISA and qRT-PCR were applied respectively to detected cytokines and miR-144-3p in 129 LUAD, 54 LUSC and 40 healthy donors. Moreover, miRNA array was carried out for miRNA profiling. TCGA database was employed for validation, and follow up data were collected for prognosis evaluation. MTT assay and western-blot were carried out for proliferation evaluation. Conclusions: In LUAD patients, the serum IL-1 beta level was correlated with miR-144- 3p may affect miR-144-3p at transcriptional level. Both of them were independent risk factors for LUAD prognosis. In addition, IL-1 beta and miR-144-3p might mediate inflammation-promoted tumorigenesis in LUAD patients.
引用
收藏
页码:85876 / 85887
页数:12
相关论文
共 30 条
  • [1] [Anonymous], MOL ONCOLOGY
  • [2] A miR-34a-Numb Feedforward Loop Triggered by Inflammation Regulates Asymmetric Stem Cell Division in Intestine and Colon Cancer
    Bu, Pengcheng
    Wang, Lihua
    Chen, Kai-Yuan
    Srinivasan, Tara
    Murthy, Preetish Kadur Lakshminarasimha
    Tung, Kuei-Ling
    Varanko, Anastasia Kristine
    Chen, Huanhuan Joyce
    Ai, Yiwei
    King, Sarah
    Lipkin, Steven M.
    Shen, Xiling
    [J]. CELL STEM CELL, 2016, 18 (02) : 189 - 202
  • [3] Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
    Campbell, Joshua D.
    Alexandrov, Anton
    Kim, Jaegil
    Wala, Jeremiah
    Berger, Alice H.
    Pedamallu, Chandra Sekhar
    Shukla, Sachet A.
    Guo, Guangwu
    Brooks, Angela N.
    Murray, Bradley A.
    Imielinski, Marcin
    Hu, Xin
    Ling, Shiyun
    Akbani, Rehan
    Rosenberg, Mara
    Cibulskis, Carrie
    Ramachandran, Aruna
    Collisson, Eric A.
    Kwiatkowski, David J.
    Lawrence, Michael S.
    Weinstein, John N.
    Verhaak, Roel G. W.
    Wu, Catherine J.
    Hammerman, Peter S.
    Cherniack, Andrew D.
    Getz, Gad
    Artyomov, Maxim N.
    Schreiber, Robert
    Govindan, Ramaswamy
    Meyerson, Matthew
    [J]. NATURE GENETICS, 2016, 48 (06) : 607 - +
  • [4] Comprehensive molecular profiling of lung adenocarcinoma
    Collisson, Eric A.
    Campbell, Joshua D.
    Brooks, Angela N.
    Berger, Alice H.
    Lee, William
    Chmielecki, Juliann
    Beer, David G.
    Cope, Leslie
    Creighton, Chad J.
    Danilova, Ludmila
    Ding, Li
    Getz, Gad
    Hammerman, Peter S.
    Hayes, D. Neil
    Hernandez, Bryan
    Herman, James G.
    Heymach, John V.
    Jurisica, Igor
    Kucherlapati, Raju
    Kwiatkowski, David
    Ladanyi, Marc
    Robertson, Gordon
    Schultz, Nikolaus
    Shen, Ronglai
    Sinha, Rileen
    Sougnez, Carrie
    Tsao, Ming-Sound
    Travis, William D.
    Weinstein, John N.
    Wigle, Dennis A.
    Wilkerson, Matthew D.
    Chu, Andy
    Cherniack, Andrew D.
    Hadjipanayis, Angela
    Rosenberg, Mara
    Weisenberger, Daniel J.
    Laird, Peter W.
    Radenbaugh, Amie
    Ma, Singer
    Stuart, Joshua M.
    Byers, Lauren Averett
    Baylin, Stephen B.
    Govindan, Ramaswamy
    Meyerson, Matthew
    Rosenberg, Mara
    Gabriel, Stacey B.
    Cibulskis, Kristian
    Sougnez, Carrie
    Kim, Jaegil
    Stewart, Chip
    [J]. NATURE, 2014, 511 (7511) : 543 - 550
  • [5] Inflammation and cancer
    Coussens, LM
    Werb, Z
    [J]. NATURE, 2002, 420 (6917) : 860 - 867
  • [6] A clinical perspective of IL-1β as the gatekeeper of inflammation
    Dinarello, Charles A.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2011, 41 (05) : 1203 - 1217
  • [7] Targeting microRNAs in cancer: rationale, strategies and challenges
    Garzon, Ramiro
    Marcucci, Guido
    Croce, Carlo M.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (10) : 775 - 789
  • [8] Establishment and comparative characterization of novel squamous cell non-small cell lung cancer cell lines and their corresponding tumor tissue
    Gottschling, Sandra
    Jauch, Anna
    Kuner, Ruprecht
    Herpel, Esther
    Mueller-Decker, Karin
    Schnabel, Philipp A.
    Xu, Elizabeth C.
    Muley, Thomas
    Sueltmann, Holger
    Bender, Christian
    Granzow, Martin
    Efferth, Thomas
    Hoffmann, Hans
    Dienemann, Hendrik
    Herth, Felix J. F.
    Meister, Michael
    [J]. LUNG CANCER, 2012, 75 (01) : 45 - 57
  • [9] Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non-Small-Cell Lung Cancer: The NVALT-4 Study
    Groen, Harry J. M.
    Sietsma, Hannie
    Vincent, Andrew
    Hochstenbag, Monique M. H.
    van Putten, John W. G.
    van den Berg, Anke
    Dalesio, Otilia
    Biesma, Bonne
    Smit, Hans J. M.
    Termeer, Arien
    Hiltermann, T. Jeroen N.
    van den Borne, Ben E. E. M.
    Schramel, Franz M. N. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4320 - 4326
  • [10] MicroRNA-217 Functions as a Tumour Suppressor Gene and Correlates with Cell Resistance to Cisplatin in Lung Cancer
    Guo, Junhua
    Feng, Zhijun
    Huang, Zhi'ang
    Wang, Hongyan
    Lu, Wujie
    [J]. MOLECULES AND CELLS, 2014, 37 (09) : 664 - 671